Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06439535 versus Avastin with paclitaxel-carboplatin in first-line advanced non-squamous NSCLC
2014-003878-16Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab-bvzr in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoint: Objective response rate. Started Feb 2015; status: completed.
02
Drugs
bevacizumab-bvzr
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-003878-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003878-16.